<li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 發布時間:2019-08-03 23:01 原文鏈接: NitrogendepedentregulationofRtg1andRtg3inTORpathway

    Many key signaling molecules are conserved from yeast to man. mTOR is a protein kinase involved in nutrient and growth factor signaling in humans that has a yeast homolog with a similar role, TOR1. Like its human counterpart, yeast TOR1 is also inhibited by rapamycin. Signaling downstream of the TOR kinase pathways regulates the nuclear localization of several transcription factors in response to the carbon and nitrogen sources in the nutritional environment. Yeast cells activate the transcription factor GLN3 through the TOR pathway to control the use of nitrogen in response to nitrogen sensing. TOR phosphorylation of GLN3 when nitrogen is abundant causes cytoplasmic localization and inactivation of this transcription factor. When nitrogen is abundant, URE2 also interacts with GLN3 to keep it out of the nucleus and repressed. TOR also regulates GLN3 through regulation of the phosphatase SIT4 that dephosphorylates GLN3 inducing nuclear localization. The preferred nitrogen sources for yeast cells are glutamine and glutamate, which are derived from TCA cycle intermediates. The use of urea or ammonia as a nitrogen source is associated with induction of genes involved in the TCA cycle by the transcription factors RTG1 and RTG3. When glutamine is present, it causes repression of RTG1 and RTG3 by TOR1. The set of genes regulated downstream of TOR affect cell growth associated processes such as translation and nutrient use. The ability of TOR to selectively regulate different sets of genes in response to either carbon or nitrogen sources indicates that TOR can interact independently with these downstream effectors.

    Contributor:

    REFERENCES: Beck, T. and Hall, M.N. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature, vol 402(6762), 1999, 689-92. Bertram PG, et al. Convergence of TOR-nitrogen and Snf1-glucose signaling pathways onto Gln3. Mol. Cell. Biol., vol 22(4), 2002, 1246-52. Cardenas ME, et al. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev., vol 13(24), 1999, 3271-79. Chan TF, Carvalho J, Riles L, and Zheng XF. A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). PNAS, vol 97(24), November 2000, 13227-32. Komeili A, Wedaman K, O'Shea E, and Powers T. Mechanism of metabolic control: Target of rapamycin signaling links nitrogen quality to the activity of the Rtg1 and Rtg3 transcription factors. J. Cell Biol., vol 151(4), November 2000, 863-78. Kulkarni AA, et al. Gln3p nuclear localization and interaction with Ure2p in Saccharomyces cerevisiae. J. Biol. Chem., vol 276(34), 2002, 32136-44. Raught B, Gingras A, and Sonenburg N. The target of rapamycin (TOR) proteins. PNAS, vol 98(13), June 2001, 7037-44. Shamji AF, Kuruvilla FG, and Schreiber SL. Partitioning the transcriptional program induced by rapamycin among the effectors of the Tor proteins. Current Biology, vol 10(24), 2000, 1574-81.



    相關文章

    “3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段

    萬物蓬勃的7月里迎來了2022年ANTOP獎的申報和評審工作。由島津企業管理(中國)有限公司申報的“3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段。獎項名稱:3CoinONE全新體驗......

    青源峰達太赫茲在國際頂級期刊《TrendsinBiotechnology》發文

    青島青源峰達太赫茲科技有限公司研發團隊在國際頂級期刊《TrendsinBiotechnology》(譯名:《生物技術趨勢》)在線發表題為“THzmedicalimaging:frominvitroto......

    科學家將人工智能技術成功用于蛋白質復合物結構預測

    蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......

    發力癌癥分子病理診斷,無錫臻和全資收購TissueofOrigin?

    2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......

    這3個雜志撤回中國學者249篇文章,包含上交、中山等名校

    2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......

    firstinclass胃癌一線療法獲FDA突破性療法

    安進宣布,美國FDA授予其在研firstinclass單抗bemarituzumab突破性療法認定,與改良FOLFOX6化療方案(亞葉酸鈣、氟尿嘧啶和奧沙利鉑)聯用,一線治療FGFR2b過表達和HER......

    金屬所三維伊辛模型精確解研究取得進展

    2007年,中國科學院金屬研究所研究員張志東在英國《哲學雜志》(PhilosophicalMagazine)上發表論文,提出兩個猜想,并在猜想基礎上推定出三維伊辛模型的精確解。被《哲學雜志》審稿人評價......

    腫瘤治療的強心劑,中國學者開發腫瘤治療新策略

    磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......

    腫瘤治療的強心劑,中國學者開發腫瘤治療新策略

    磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......

    llumina宣布推出新型基因分型芯片|支持AllofUs研究計劃

    2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......

    <li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 1v3多肉多车高校生活的玩视频